Advertisement
TAK vs TEVA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TAK is a Buy and TEVA is a StrongBuy.
Aroon Indicator for TAK shows an upward move is likely
TAK's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 283 similar instances where the Aroon Indicator showed a similar pattern. In 157 of the 283 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 55%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on TAK as a result. In 42 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 44%.
Following a +2.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where TAK advanced for three days, in 157 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for TAK moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 16 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 29 of 59 cases where TAK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 49%.
The Moving Average Convergence Divergence Histogram (MACD) for TAK turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 21 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TAK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.
TAK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.009) is normal, around the industry mean (6.379). P/E Ratio (-0.402) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.425) is also within normal values, averaging (2.202). Dividend Yield (0.056) settles around the average of (0.062) among similar stocks. P/S Ratio (1.968) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 17 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. TAK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
TEVA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for TEVA turned positive on November 03, 2026. Looking at past instances where TEVA's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on TEVA as a result. In 53 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
Following a +2.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in 229 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 208 of 282 cases where TEVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
TEVA broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.410) is normal, around the industry mean (6.379). P/E Ratio (68.726) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.202). Dividend Yield (0.008) settles around the average of (0.062) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (183.387).
TAK | TEVA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 17 | 5 | |
SMR RATING 1..100 | 91 | 72 | |
PRICE GROWTH RATING 1..100 | 38 | 39 | |
P/E GROWTH RATING 1..100 | 97 | 7 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TAK's Valuation (8) in the Pharmaceuticals Major industry is significantly better than the same rating for TEVA (77) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew significantly faster than TEVA’s over the last 12 months.
TEVA's Profit vs Risk Rating (5) in the Pharmaceuticals Generic industry is in the same range as TAK (17) in the Pharmaceuticals Major industry. This means that TEVA’s stock grew similarly to TAK’s over the last 12 months.
TEVA's SMR Rating (72) in the Pharmaceuticals Generic industry is in the same range as TAK (91) in the Pharmaceuticals Major industry. This means that TEVA’s stock grew similarly to TAK’s over the last 12 months.
TAK's Price Growth Rating (38) in the Pharmaceuticals Major industry is in the same range as TEVA (39) in the Pharmaceuticals Generic industry. This means that TAK’s stock grew similarly to TEVA’s over the last 12 months.
TEVA's P/E Growth Rating (7) in the Pharmaceuticals Generic industry is significantly better than the same rating for TAK (97) in the Pharmaceuticals Major industry. This means that TEVA’s stock grew significantly faster than TAK’s over the last 12 months.
| TAK | TEVA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 42% | N/A |
| Stochastic ODDS (%) | 1 day ago 49% | 1 day ago 60% |
| Momentum ODDS (%) | 1 day ago 44% | 1 day ago 68% |
| MACD ODDS (%) | 1 day ago 47% | 1 day ago 82% |
| TrendWeek ODDS (%) | 1 day ago 50% | 1 day ago 76% |
| TrendMonth ODDS (%) | 1 day ago 49% | 1 day ago 73% |
| Advances ODDS (%) | 7 days ago 50% | 3 days ago 76% |
| Declines ODDS (%) | 1 day ago 45% | 7 days ago 66% |
| BollingerBands ODDS (%) | 1 day ago 64% | 2 days ago 67% |
| Aroon ODDS (%) | 1 day ago 55% | 1 day ago 74% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
TAK’s FA Score shows that 2 FA rating(s) are green while TEVA’s FA Score has 2 green FA rating(s).
- TAK’s FA Score: 2 green, 3 red.
- TEVA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
TAK’s TA Score shows that 5 TA indicator(s) are bullish while TEVA’s TA Score has 4 bullish TA indicator(s).
- TAK’s TA Score: 5 bullish, 4 bearish.
- TEVA’s TA Score: 4 bullish, 3 bearish.
Price Growth
TAK (@Pharmaceuticals: Generic) experienced а +0.87% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was +1.17% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.
Reported Earning Dates
TAK is expected to report earnings on Jan 28, 2027.
TEVA is expected to report earnings on Feb 10, 2027.
Industries' Descriptions
@Pharmaceuticals: Generic (-0.20% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
TAK and
Correlation & Price change
A.I.dvisor indicates that over the last year, TAK has been loosely correlated with HLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TAK jumps, then HLN could also see price increases.
| Ticker / NAME | Correlation To TAK | 1D Price Change % | ||
|---|---|---|---|---|
| TAK | 100% | -0.43% | ||
| HLN - TAK | 43% Loosely correlated | +0.44% | ||
| ZTS - TAK | 31% Poorly correlated | +0.13% | ||
| COLL - TAK | 29% Poorly correlated | +1.39% | ||
| ANIK - TAK | 28% Poorly correlated | +3.56% | ||
| PRGO - TAK | 27% Poorly correlated | -1.66% | ||
More | ||||
TEVA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.
| Ticker / NAME | Correlation To TEVA | 1D Price Change % | ||
|---|---|---|---|---|
| TEVA | 100% | +1.98% | ||
| AMRX - TEVA | 40% Loosely correlated | +1.54% | ||
| VTRS - TEVA | 35% Loosely correlated | +1.01% | ||
| COLL - TEVA | 28% Poorly correlated | +1.39% | ||
| ELAN - TEVA | 27% Poorly correlated | -1.05% | ||
| TAK - TEVA | 26% Poorly correlated | -0.43% | ||
More | ||||